No press releases found.
Bayer-backed Boundless Bio stock down 8% after $100M IPO
Seeking Alpha News (Thu, 28-Mar 1:51 PM ET)
Bayer-backed Boundless Bio sees stock fall 8% after $100M IPO
Seeking Alpha News (Thu, 28-Mar 1:51 PM ET)
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
Boundless Bio trades on the NASDAQ stock market under the symbol BOLD.
As of March 28, 2024, BOLD stock price climbed to $14.25 with 1,748,829 million shares trading.
BOLD has a market cap of $316.91 million. This is considered a Small Cap stock.